Home › NDC Lookup › RxCUI directory › RxCUI 2166094

Halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical Lotion [Duobrii] — RxCUI 2166094

Name: Halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical Lotion [Duobrii] (RxCUI 2166094)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2166094 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2166094

Official nameHalobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical Lotion [Duobrii]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asDuobrii 0.01 % / 0.045 % Topical Lotion

FDA products mapped1

Package NDCs mapped2

Reported Medicaid activity (SDUD)191 prescriptions · 2 state & territory Medicaid programs · latest period Q3 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Halobetasol Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Halobetasol topical is used to treat inflammatory skin conditions — conditions that cause redness, swelling, and itching. The ointment form is used broadly for skin conditions that...
You should use halobetasol topical for no longer than two consecutive weeks, and no more than 50 grams total per week. It's a very potent steroid, and using it longer or in larger...
Yes — avoid applying halobetasol to your face, groin, or underarms. These areas have thinner skin and absorb much more of the medication, increasing your risk of side effects. Also...
Are there places I should not apply this?

📖 Read our full Halobetasol Topical guide →

🕸️ Concept Web — How Halobetasol propionate 0.1 MG/ML / tazarotene 0.... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical Lotion [Duobrii] RxCUI 2166094 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 4

The active substance itself — no strength, form, or brand attached yet.
- Halobetasol 41208 IN
- Tazarotene 83947 IN
- Halobetasol / tazarotene 2166088 MIN
- Halobetasol propionate 45318 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Duobrii 2166090 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Halobetasol / tazarotene Topical Lotion 2166087 SCDF
- Halobetasol propionate / tazarotene Topical Lotion 2649130 SCDFP
- Halobetasol / tazarotene Topical Product 2166086 SCDG
- Halobetasol propionate / tazarotene Topical Product 2660331 SCDGP
- Halobetasol / tazarotene Topical Lotion [Duobrii] 2166092 SBDF
- Halobetasol propionate / tazarotene Topical Lotion [Duobrii] 2656830 SBDFP
- Duobrii Topical Product 2166093 SBDG
- Topical Lotion 316983 DF
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical Lotion 2166089 SCD
- Halobetasol propionate 0.1 MG/ML 2101709 SCDC
- Tazarotene 0.45 MG/ML 2166085 SCDC
- Halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML [Duobrii] 2166091 SBDC

Showing up to 8 concepts per family — 17 of 18 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical Lotion SCD · 2166089
Halobetasol propionate 0.1 MG/ML SCDC · 2101709
Tazarotene 0.45 MG/ML SCDC · 2166085
Halobetasol / tazarotene Topical Lotion SCDF · 2166087
Halobetasol propionate / tazarotene Topical Lotion SCDFP · 2649130
Halobetasol / tazarotene Topical Product SCDG · 2166086
Halobetasol propionate / tazarotene Topical Product SCDGP · 2660331

Brand-Name Concepts

Halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML [Duobrii] SBDC · 2166091
Halobetasol / tazarotene Topical Lotion [Duobrii] SBDF · 2166092
Halobetasol propionate / tazarotene Topical Lotion [Duobrii] SBDFP · 2656830
Duobrii Topical Product SBDG · 2166093
Duobrii BN · 2166090

📦 FDA Products & Package NDCs

1 product · 2 package NDCs

2 package NDCs map to RxCUI 2166094 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00187-0653-01	1 TUBE in 1 CARTON (0187-0653-01) / 100 g in 1 TUBE	Duobrii	Bausch Health US, LLC	2019-04-25
00187-0653-03	6 TUBE in 1 CARTON (0187-0653-03) / 3 g in 1 TUBE	Duobrii	Bausch Health US, LLC	2019-04-25

Observed labelers: Bausch Health US, LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.